Text Size

Venous Thromboembolism Taskforce Audit Program

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00535171
First received: September 25, 2007
Last updated: January 21, 2010
Last verified: January 2010
History of Changes
  Purpose

To determine the effect of an interventional campaign run by a dedicated "VTE Nurse Educator" over a 6-month period and the effect on prophylaxis rates.

To determine the proportion of medically admitted patients with risk factors for VTE.

To assess and compare the use of venous thromboembolism (VTE) prophylaxis in hospitalized medical patients versus recommendations and current guidelines.

To determine the patient characteristics of those deemed to be at risk of VTE. To determine the proportion of patients receiving appropriate thromboprophylaxis for their risk.

To determine the type and duration (where possible) of prophylaxis used.


Condition
Venous Thrombosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Venous Thromboembolism Taskforce Audit Program

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sanofi:

Enrollment: 8764
Study Start Date: June 2007
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Venous thromboembolism in medical patients bedridden due to acute illness.

Criteria

Inclusion Criteria:

  • Hospital admission for an acute illness with an in-patient hospital stay of 3 days or more.

Exclusion Criteria:

  • Patients who have undergone any type of surgery during current admission
  • Patients who are admitted to a ward or department that is excluded from this study e.g psychiatric, paediatric, maternity, intensive care unit, coronary care unit.
  • Prior enrollment in this protocol during current admission
  • Prior enrollment in a VTE study involving pharmaceutical or mechanical treatment within last 90 days.
  • Admission for suspected or diagnosed deep vein thrombosis

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00535171

Locations
Australia
Sanofi-Aventis
MacQuarie Park, Australia
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Fiona Howard Sanofi
  More Information

No publications provided

Responsible Party: Medical Affairs Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00535171     History of Changes
Other Study ID Numbers: DIREG_L_01927
Study First Received: September 25, 2007
Last Updated: January 21, 2010
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Additional relevant MeSH terms:
Thromboembolism
Thrombosis
Venous Thrombosis
Venous Thromboembolism
 Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 19, 2013